| Biological Information | |
|---|---|
| Background Information: | Ibrutinib (PCI-32765, Imbruvica) is an FDA approved drug that targets B-cell malignancies and is approved for treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia. Ibrutinib is an orally-bioavailable compound that is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Also inhibits YES and other SRC family tyrosine kinases. Provided as 5 mg of dry powder. |
| Target Name: | Ibrutinib |
| Usage | |
| Product Type: | Control Ligands & Inhibitors |
| Application: | Drug Discovery & Development |
| Storage Conditions: | Store at -20°C. Please avoid multiple freeze/thaw cycles. |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Additional Information | |
| Brand: | DiscoverX |
Ibrutinib (PCI-32765)
Ibrutinib (PCI-32765) is an inhibitor of BTK, YES, and other SRC tyrosine kinases. This product is provided as 5 mg of dry powder.
Datasheets
92-1243 Datasheet
View Document